Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Paclitaxel, Trastuzumab, and Pertuzumab as Pre-Operative Therapy for Inflammatory Breast Cancer
NCT01796197Phase 2Completed
- Sponsor
- Dana-Farber Cancer Institute
- Start
- Aug 2013
- Primary completion
- Jun 2018
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of pertuzumab in inflammatory breast cancer (IBC), sponsored by Dana-Farber Cancer Institute. Primary endpoints: Pathologic Complete Response at 18 weeks and Residual Cancer Burden Rate at 18 weeks. Started Aug 2013; status: completed.
02
Drugs
pertuzumab
03
Conditions
inflammatory breast cancer (IBC)
Beyond the preview
Go deeper on NCT01796197.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT01796197.